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Parathyroid hormone (PTH) is secreted in the parathyroid glands. It has 
a role in bone remodeling, a process in which calcium transfers from the 
bone to the blood stream and back to the bone. As PTH levels rise, more 
calcium is released from the bones to the blood, as levels decrease, 
calcium re-accumulates in the bones. It is thought that PTH is secreted 
in response to low blood serum calcium levels to maintain them, but 
here we propose that PTH levels are directly and inversely related to 
Vitamin D levels. This has implications for several illnesses including 
low bone mineral density (BMD) and osteoporosis.
The following research [1] shows the negative correlation between 
Vitamin D levels and serum PTH: “Serum PTH correlated negatively 
with serum 25OHD (Vitamin D). This significant negative correlation 
was observed in all regions. When serum 25OHD was <25, 25–50, or 
more than 50 nmol/L, respectively, mean serum PTH levels were 4.8, 
4.1, and 3.5 pmol/L, respectively…. [1]”
Another study, by Dhanwal et al. [2] found a negative correlation 
between PTH levels and Vitamin D levels and a positive correlation 
between Vitamin D levels and BMD. They conclude that “hyperthyroid 
patients with concomitant Vitamin D deficiency had lower BMD 
compared with Vitamin D-sufficient patients [2].”
Another study of Postmenopausal Osteoporotic Women [3] found them 
to be severely deficient in Vitamin D. “Mean serum 25(OH)D level was 
26.8 and overall, 64% of women had serum levels <30 ng mL−1.” They 
also observed the negative correlation between Vitamin D and PTH 
levels [3].
A study [4] examining treatment of sodium fluoride, Vitamin D and 
Calcium found “an increase in new bone formation in all patients.” They 
conclude that “In order to restore bone mass in osteoporotic subjects, 
a therapeutic regimen of 50 mg of sodium fluoride and at least 900 
mg of calcium per day and 50,000 units of Vitamin D twice weekly is 
recommended [4].”
To conclude, it seems that decreased levels of Vitamin D lead to 
hyperparathyroidism and therefore to reduction in BMD. It is advised 
to continue studying Vitamin D for its relationship with PTH and for its 
possible role in the treatment and prevention of osteoporosis and low 
BMD status.
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